Treatment with inebilizumab was associated with continued improvement in patients with AChR+ generalized myasthenia gravis, according to 52-week results from the MINT trial.

Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with ...

At week 52, results showed AChR+ patients treated with inebilizumab continued to improve based on the change from baseline in MG-ADL score vs placebo. Treatment with inebilizumab was associated ...

New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Data from the study showed that treatment with Uplizna ‘demonstrated durable and sustained efficacy’ in AChR-positive (AChR+) gMG patients over 52 weeks. These findings were assessed using the ...